TriSalus Life Sciences Welcomes Renowned Expert Riad Salem
TriSalus Life Sciences Welcomes Renowned Expert Riad Salem
TriSalus Life Sciences® Inc. (NASDAQ: TLSI), a leading oncology company dedicated to advancing outcomes for patients battling liver and pancreatic cancer, proudly announces the appointment of Dr. Riad Salem to its Scientific Advisory Board (SAB). This pivotal decision marks a significant enhancement in their commitment to utilizing cutting-edge delivery technology and innovative immunotherapy, including nelitolimod.
Dr. Riad Salem's Impactful Contributions
Dr. Riad Salem brings a wealth of experience to TriSalus as he serves as the Chief of Interventional Radiology and a Professor of Radiology, Surgery, and Medicine. His groundbreaking contributions to radiological research have made him a recognized leader in developing advanced treatments for liver cancer. Mary Szela, CEO and President of TriSalus, expressed her excitement regarding Dr. Salem’s appointment, stating, “We are thrilled to welcome Dr. Salem to our SAB. His extensive expertise will be invaluable as we advance our mission of improving patient outcomes.”
Significance of Dr. Salem’s Role
Dr. Salem's experience includes leading the LEGACY study, a groundbreaking project that showcased the efficacy of y90 treatments, leading to improved response rates and extended survival for patients. His role within the SAB will be instrumental as TriSalus rolls out its new DELIVER program, a comprehensive clinical initiative aimed at gathering robust data to validate the effectiveness of the Pressure Enabled Drug Delivery™ (PEDD™) method and nelitolimod for challenging patient populations.
Exploring Innovative Treatment Methods
In his own words, Dr. Salem conveyed his enthusiasm for joining TriSalus, particularly given the pressing need for enhanced treatment methodologies for complex liver and pancreatic cancer cases. He expressed eagerness to collaborate with TriSalus, focusing on their innovative immunotherapeutic agent nelitolimod and their advanced drug delivery system, TriNav®.
About TriSalus’s Advanced Technologies
TriSalus Life Sciences specializes in oncology-focused medical technology, pioneering disruptive drug delivery solutions to augment therapeutic delivery for liver and pancreatic tumors. The company’s platform incorporates proprietary devices combining advanced drug delivery techniques with investigational immunotherapies. Among their FDA-cleared devices is the TriNav® Infusion System, designed for hepatic arterial infusion, along with the Pancreatic Retrograde Venous Infusion System specifically for pancreatic tumors.
The Promise of Pressure-Enabled Drug Delivery
The PEDD methodology represents a breakthrough in addressing the anatomical limitations typically associated with arterial infusion for the pancreas. By modulating pressure and flow, this innovative technique aims to ensure that a greater volume of therapeutic agents reach the tumor while minimizing exposure to healthy tissues, significantly enhancing patient outcomes.
Nelitolimod, the investigational immunotherapeutic agent from TriSalus, targets the often immunosuppressive environment that characterizes many tumors, particularly in the liver and pancreas. The reasoning behind this focus lies in the frustrating reality that many existing immunotherapies may prove ineffective in these areas. Research indicates that nelitolimod, particularly when delivered via PEDD, may yield favorable immune responses not only locally within the liver but systemically as well, thereby broadening the potential treatment avenues.
Commitment to Advancing Patient Care
TriSalus is dedicated to enhancing patient care by collaborating with leading cancer centers nationwide and leveraging extensive immuno-oncology knowledge. Their mission is to foster innovation that translates into better outcomes for patients facing the daunting challenges of cancer.
About TriSalus Life Sciences
Founded on a commitment to advancing oncology treatment methods, TriSalus Life Sciences strives to improve therapeutic delivery to liver and pancreatic tumors through its inventive technologies. The company’s innovative approaches, tempered by rigorous research and strong partnerships, position it at the forefront of fighting these challenging cancers.
Frequently Asked Questions
What is the role of Dr. Riad Salem at TriSalus?
Dr. Riad Salem has been appointed to the Scientific Advisory Board, where he will contribute his expertise in interventional radiology and oncology to advance the company's mission.
What is the significance of the DELIVER program?
The DELIVER program aims to provide robust data to validate TriSalus's innovative Pressure Enabled Drug Delivery™ and its investigational treatments for challenging cancer cases.
What advancements does TriSalus focus on?
TriSalus is focused on improving treatment outcomes for patients with liver and pancreatic cancer through innovative drug delivery technologies and immunotherapy.
How does the PEDD technology improve patient outcomes?
PEDD technology enhances therapeutic delivery directly to tumors while minimizing exposure to healthy tissues, potentially leading to better treatment results.
What is nelitolimod and its purpose?
Nelitolimod is an investigational immunotherapeutic agent designed to combat the immunosuppressive environment created by cancer, enhancing treatment efficacy in liver and pancreatic cancers.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- WAVE Life Sciences Gain Momentum with Positive Clinical Results
- Geoquip Marine Welcomes Rune Olav Pedersen as New CEO
- Investors of Equity LifeStyle Properties Should Act Now
- Trump Discusses Life Threats and Increased Security Measures
- Act Now: Lifecore Biomedical Class Action Against LFCR
- Cassava Sciences Faces SEC Charges; Shares Decline After News
- Cassava Sciences Settles SEC Investigation Ahead of Trials
- Cordell & Cordell Welcomes Joseph P. Breda as New CEO
- Cassava Sciences Settles SEC Inquiry on Clinical Trial Claims
- MES Welcomes Marvin Riley as New CEO, Transitioning Leadership
Recent Articles
- Experience the New Shock Top LiiT Hard Iced Tea: A Flavor Hit
- Gain Therapeutics Invites You to Learn About GT-02287 Webinar
- Laser Photonics and Brokk Team Up for Asia-Pacific Laser Solutions
- Sage Therapeutics Ends Collaboration with Biogen on SAGE-324
- Virtu Financial Celebrates Exceptional Women in Finance Leaders
- Eyenovia Introduces Clobetasol for Ocular Surgery Relief
- Strategic Alliance to Elevate Ready-to-Use Solutions in Pharma
- Key Carbon and Marex Group Collaborate on Carbon Initiatives
- BankID BankAxept Moves Forward with Criipto Acquisition Strategy
- Promising Results for Pasithea's PAS-004 in Advanced Cancer Trials
- Aethon United Completes Tender Offer for Senior Notes Successfully
- Goliath Resources Expands Financing to Over $16 Million
- Telehealth Satisfaction Study Reveals Varied Patient Experiences
- BlackRock and Santander Strengthen Ties for Project Financing
- N-able Achieves Triple Win in Workplace Culture Awards
- Celebrating 20 Years of Profit Launch Workshops for Contractors
- Monex Canada Strengthens Team with Key Appointments for Growth
- Truist Foundation Commits $500,000 for Hurricane Relief Efforts
- Marqeta Partners with Found for Enhanced Business Solutions
- Sekur Private Data Ltd. Expands into Latin America Market
- Everseen's Innovative Vision AI Drives Remarkable Retail Growth
- Innovative AI Tool Launches to Safeguard Nature in Development
- Unveiling the AI-Driven Nature Risk Tool by AECOM and SMI
- VersaBank Celebrated for Innovation in Banking Technology
- Discover Purcell Properties at the Dublin Property Expo
- Investing in Growth: New State Capital Partners and Expo Group
- Discover the Latest Innovations from Descartes at Industry Forum
- Freightos Partners with HNA Cargo to Enhance Air Cargo Services
- Market Gains on Micron's Surge and China’s Stimulus Moves
- Exciting Deals Await: Join Wayfair's Holiday Way Day Sale!
- Southwest Airlines Launches Exciting New Transformation Plan
- Experience Stunning Clarity with TrueCut Motion Technology
- Zefr Expands Brand Safety Features to Tackle Misinformation
- Big Lots Launches Affiliate Program for Influential Creators
- Celebrating Innovation: Garmin Health Awards Highlight Progress
- Innovative Solutions for Accelerating Building Decarbonisation
- Join the Movement to Free Edwin Rubis from His Sentence
- Enhancements in Keeper Security's iOS Autofill Capabilities
- Elevate Your Coffee Experience This National Coffee Day
- CEO Warrior Highlights Lifelong Learning at Upcoming Event
- Southwest Airlines Introduces Innovative Plan to Enhance Growth
- Southwest Airlines Welcomes Robert Fornaro to Its Board
- WeBank and Oliver Wyman Examine Digital Banking Trends Globally
- Descartes Systems Group Reveals Innovations for Supply Chain 2024
- B. Riley Predicts Bright Future for InfuSystems as Growth Looms
- HSBC Analysts Forecast Potential Fed Rate Hikes by 2026
- Amazon’s Future: Embracing AI and Revamping Corporate Culture
- ANI Pharmaceuticals Launches FDA-Approved Ketoconazole Shampoo
- AECOM Secures Major Contract for Zero Emission Bus Initiative
- NextRNA Therapeutics Welcomes Jesse Smith, PhD as CSO